Biosynthetic Semaglutide Slashes HbA1c by 1.86% and Weight by 7.84 kg in Real-World T2DM Patients

Managing Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge, particularly in cost-constrained regions where access to advanced therapies can be limited. Current standard-of-care often struggles to achieve optimal glycemic control and address associated comorbidities like obesity, leading to long-term complications. Glucagon-like peptide-1 receptor (GLP-1R) agonists like semaglutide have revolutionized T2DM treatment by effectively lowering HbA1c and promoting weight loss, but their cost can be a barrier. This study explores the real-world utility of biosynthetic semaglutide, a more accessible alternative, in routine outpatient care.

This 30-week, prospective, multicenter, non-interventional study enrolled 217 adults with Type 2 Diabetes Mellitus (T2DM) in Pakistan who were initiating biosynthetic semaglutide as part of their routine outpatient care. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to the end of the study (EOS). Secondary endpoints included changes in body weight, body mass index (BMI), waist circumference, and patient-reported outcomes assessed via DTSQs and SF-36v2 questionnaires. Safety and tolerability were also monitored throughout the study period.

Biosynthetic semaglutide demonstrated clinically meaningful improvements across key metabolic parameters. Mean HbA1c significantly decreased from 9.27% at baseline to 7.41% at EOS, representing a mean reduction of -1.86% (p < 0.001). At EOS, 76.6% of patients achieved an HbA1c < 8.0%, and 38.7% reached the more stringent target of < 7.0%.

Mean body weight decreased by -7.84 kg (p < 0.001), with a remarkable 76.5% of patients achieving ≥ 5% weight loss. Significant reductions were also observed in body mass index and waist circumference. Patient-reported outcomes showed significant improvements in treatment satisfaction and physical quality of life. The safety profile was consistent with established semaglutide therapy, with adverse events predominantly non-serious and gastrointestinal in nature. Notably, no severe hypoglycaemic episodes were reported.